Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1238097 in Advanced Malignancies
NCT02369029Phase 1Terminated
- Sponsor
- Bayer
- Start
- Mar 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of BAY 1238097 in solid tumor (advanced stage), lymphoma, hepatocellular carcinoma (HCC) and 5 more, sponsored by Bayer. Primary endpoint: Incidence of Dose-Limiting Toxicities. Started Mar 2015; status: terminated.
02
Drugs
BAY 1238097
03
Conditions
solid tumor (advanced stage)lymphomahepatocellular carcinoma (HCC)lung cancerNUT carcinoma (NMC)
Beyond the preview
Go deeper on NCT02369029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369029.